李軍民(上海瑞金醫院血液科主任醫師)

李軍民，主任醫師，博士研究生導師，現任上海交通大學醫學院附屬瑞金醫院血液科主任，中華醫學會血液學分會常委，上海醫學會血液學分會主委。

基本介紹

• 中文名稱：李軍民
• 職業：醫生
• 畢業院校：上海交通大學
• 臨床職稱：主任醫師
• 專業：血液內科
• 教學職稱：博士研究生導師
• 執業地點：上海交通大學醫學院附屬瑞金醫院

研究方向

血液系統惡性腫瘤的發病機制及臨床治療。

教育經歷

上海交通大學博士

工作經歷

上海交通大學醫學院附屬瑞金醫院血液科主任

社會任職

民建中央委員

學術兼職

國家健康科普專家庫成員

中華醫學會血液學分會常委

上海醫學會血液學分會主委

學術雜誌審稿人

《上海醫學》審稿人

學術著作編委

《臍帶血造血幹細胞移植與倫理原則》編委

獲獎及榮譽稱號

2019年教育部科學研究優秀成果獎（科學技術）二等獎

主要承擔科研項目

負責科技部重點專項、國家自然基金面上項目

第一或通訊作者SCI文章目錄

1. Zi-Zhen Xu, Wan-Bin Fu, Zhen Jin, Pei Guo, Wen-Fang Wang & Jun-Min Li. Reactive Oxygen Species Mediate Oridonin-Induced Apoptosis through DNA Damage Response and Activation of JNK Pathway in Diffuse Large B cell Lymphoma. Leukemia & Lymphoma 2015.

2. Kai Qing, Zhen Jin, Wanbin Fu, Wenfang Wang, Zhao Liu, Xiaoyang Li, Zizhen Xu and Junmin Li. Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma. Journal of Hematology & Oncology. 2016 Aug 23;9(1):72. doi: 10.1186/s13045-016-0303-0.

3. Xiaoyang Li, Yunxiang Zhang, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol. 2015 Jan;94(1):57-63.

4. Xiaoyang Li, Hongming Zhu, et al. The Time to Clearance of Peripheral Blood Blasts Predicts Complete Remission and Survival in Chinese Adults with Acute Myeloid Leukemia. Acta Haematol. 2016;135(4):217-23.

5. Xiaoyang Li, Yu Zheng, et al. Risk of Onset of Hematological Malignancies in Patients Infected with the Hepatitis B Virus: Results from a Large-Scale Retrospective Cohort Study in China. Acta Haematol. 2017 May 18;137(4):209-213.

6. Hongming Zhu, Jiong Hu, Xiaoyang Li, et al. All-trans retinoic acid and arsenic combination therapy benefits low-to-intermediate-risk patients with newly diagnosed acute promyelocytic leukaemia: a long-term follow-up based on multivariate analysis. Br J Haematol.

7. Long J, Fang WY, Chang L, Gao WH, Shen Y, Jia MY, Zhang YX, Wang Y, Dou HB, Zhang WJ, Zhu J, Liang AB, Li JM, Hu J. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia. 2017 Dec;31(12):2761-2770. doi: 10.1038/leu.2017.130.

8. Chen L, Guo P, Zhang Y, Li X, Jia P, Tong J, Li J. Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells. Leukemia research. 2017 Sep;60:44-52. doi: 10.1016/j.leukres.2017.06.007.

9. Zhu H, Hu J, Chen L, Zhou W, Li X, Wang L, Zhao X, Zhang Y, Zhao H, Wang A, Chen Y, Sun H, Chen Q, Chen Y, Zhao W, Mi J, Shen Z, Wang Z, Chen Z, Chen S, Li J. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. Blood. 2016 Sep 15;128(11):1525-8.

10. Zhen Jin, Kai Qing, Yuan Ouyang, Zhao Liu, Wenfang Wang, Xiaoyang Li, Zizhen Xu and Junmin Li. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma. Journal of Experimental & Clinical Cancer Research (2016) 35:52.

11. Jin Z, Xiang R, Qing K, Li X, Zhang Y, Wang L, Zhu H, Mao Y, Xu Z, Li J. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review. Ann Hematol. 2018 Aug;97(8):1327-1335. doi: 10.1007/s00277-018-3368-8.

12. Xu ZZ, Shen JK, Zhao SQ, Li JM. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 Jun; 9(6):1451-1460. doi: 0.1080/10428194.2017. 379077

著作譯作

《瑞金醫院血液科疑難病例討論集》